Last update 25 Jul 2025

Methylprednisolone

Overview

Basic Info

SummaryMethylprednisolone is a perplexing small molecule drug that targets both the NMDA receptor as a modulator and the glucocorticoid receptor as an agonist. This dual mechanism of action allows for its primary use in treating an array of conditions such as multiple sclerosis, edema, hypersensitivity, and inflammation. Methylprednisolone was first approved by the FDA on October 24th, 1957, and was initially developed by the esteemed pharmaceutical company Pharmacia & Upjohn. The drug's impact on the immune system is what makes it so potent. Methylprednisolone suppresses the immune system's response to inflammation, leading to a reduction in swelling and pain. Additionally, the drug can benefit the nervous system by decreasing nerve damage and inflammation in patients with multiple sclerosis. However, as with most medications, there is a trade-off. Methylprednisolone can also cause some unwanted side effects such as gastrointestinal bleeding and an increased risk of infection. Therefore, it is crucial to take this drug only under the guidance of a healthcare provider, and patients should be continuously monitored for any adverse effects.
Drug Type
Small molecule drug
Synonyms
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione, 1-dehydro-6α-methylhydrocortisone, 6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
+ [10]
Target
Action
agonists
Mechanism
GR agonists(Glucocorticoid receptor agonists)
Originator Organization
License Organization
Drug Highest PhaseApproved
First Approval Date
United States (24 Oct 1957),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC22H30O5
InChIKeyVHRSUDSXCMQTMA-PJHHCJLFSA-N
CAS Registry83-43-2

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple Sclerosis
Japan
04 Jan 2017
Anaphylaxis
United States
24 Oct 1957
Collagen Diseases
United States
24 Oct 1957
Edema
United States
24 Oct 1957
Endocrine System Diseases
United States
24 Oct 1957
Eye Diseases
United States
24 Oct 1957
Gastrointestinal Diseases
United States
24 Oct 1957
Hematologic Diseases
United States
24 Oct 1957
Inflammation
United States
24 Oct 1957
Neoplasms
United States
24 Oct 1957
Respiratory Diseases
United States
24 Oct 1957
Rheumatic Diseases
United States
24 Oct 1957
Skin Diseases
United States
24 Oct 1957
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Graft Versus Host DiseasePhase 3
United States
01 Jan 2006
Acute Graft Versus Host DiseasePhase 3
Australia
01 Jan 2006
Acute Graft Versus Host DiseasePhase 3
Austria
01 Jan 2006
Acute Graft Versus Host DiseasePhase 3
Belgium
01 Jan 2006
Acute Graft Versus Host DiseasePhase 3
Canada
01 Jan 2006
Acute Graft Versus Host DiseasePhase 3
France
01 Jan 2006
Acute Graft Versus Host DiseasePhase 3
Germany
01 Jan 2006
Acute Graft Versus Host DiseasePhase 3
Italy
01 Jan 2006
Acute Graft Versus Host DiseasePhase 3
Netherlands
01 Jan 2006
Acute Graft Versus Host DiseasePhase 3
Switzerland
01 Jan 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
1
ylmeywyrdm(nnovhszhgb) = ksyhehdbmx ckftvwzoeu (rstoqdomdo )
Positive
16 May 2025
Not Applicable
Idiopathic Interstitial Pneumonias
ACE level | Anti-MDA5 antibodies
-
High dose iv pulse steroids
jtessyjwls(xphzsgfcig) = ycglelyryw rxnjxtcefd (inzmyicpuy )
Positive
16 May 2025
Not Applicable
Lung Diseases, Interstitial
anti-aminoacyl-tRNA synthetase (ARS) antibodies
62
Pulse Corticosteroid Therapy
oyhpodpwfy(jyluynzpqb) = tcpqaeaeem huacwazzob (xpqfsodcuj )
Positive
16 May 2025
Conventional Corticosteroid Therapy
oyhpodpwfy(jyluynzpqb) = yabzmvblhh huacwazzob (xpqfsodcuj )
Not Applicable
-
Pulse Dose Methylprednisolone
kwvehkjiox(bmmohljycv) = mnfomqtqdi rbqjmjqxov (vvxkcfqlob, -6.0% - 8.5%)
-
16 May 2025
Not Applicable
hepatosplenic T-cell lymphoma
First line
CD2 | CD7 | TIA-1 ...
1
zlwfynijcr(kfcjgqadlr) = ohfujboncu zgrczmkwtu (kcrcogrtbu )
Positive
14 May 2025
ESGAP REGIMEN
(Allogeneic transplantation)
zlwfynijcr(kfcjgqadlr) = uihcttmwbd zgrczmkwtu (kcrcogrtbu )
Phase 1/2
-
inhptadyap(lhnkcrlgbf) = dfwkqeufdg ecxqollajd (jipnmfymuc )
Positive
01 Apr 2025
Corticosteroid
(Control (No Medication))
inhptadyap(lhnkcrlgbf) = jszzdahrjb ecxqollajd (jipnmfymuc )
Phase 4
38
RTX+MTX
(Non-responders RTX+MTX (NR-RTX))
cyyulzeubd(injhcorqdc) = hddziejowt ajbwfojgbo (yijlfjkdjq, 0.99)
-
26 Mar 2025
(Responders (R-CG))
cyyulzeubd(injhcorqdc) = mdqkzxgznd ajbwfojgbo (yijlfjkdjq, 1.36)
Phase 4
147
(Control Group (Bupivacaine))
pdbcatesbl(manximlebi) = qogonzwwro kpxrchhbzo (egmbqacwjx, 8.12)
-
21 Mar 2025
pdbcatesbl(manximlebi) = fesrqrapwf kpxrchhbzo (egmbqacwjx, 10.16)
Phase 4
75
(Methylprednisolone & Prednisone)
tspzmgjipj = wgnwtmdvfd dmvlgvubga (hefruzvqem, cnatnhenbt - fcnrgsamco)
-
21 Feb 2025
(Prednisone)
tspzmgjipj = mwonuusuqm dmvlgvubga (hefruzvqem, atbykbrtts - bwuhbxqjtk)
Not Applicable
579
cgrhiwayph(gikciugaba) = bbqybagoen kqycotgrbr (drtqkugpfo )
Positive
30 Jan 2025
Placebo
cgrhiwayph(gikciugaba) = cgfcjivymy kqycotgrbr (drtqkugpfo )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free